Posts

GSK strikes up to $750 million deal for Chimagen blood-cancer therapy

on

AbbVie’s T-cell engager shows survival benefit in Phase 3 multiple myeloma study

on

AbbVie reports Phase 3 multiple-myeloma win, positioning etentamig for a competitive BCMA market

on

Zenbexus: BMS earns first FDA approval for CELMoD class in multiple myeloma

on

Sanofi's Sarclisa Goes Hands-Free: Will It Matter to Physicians?

on

ASCO 2026: A battle of bispecifics, Eli Lilly’s big win and more

on

Kelonia Therapeutics delivers impressive in vivo CAR-T update

on

MRD as a Decision Engine: Rethinking Oncology Trial Design from Early Phase to Registration

on

CellCentric Raises $220M Series D to Advance Inobrodib Through Pivotal Trials in Multiple Myeloma, Eyes IPO

on

Pfizer's Elrexfio Meets Phase III Primary Endpoint in Multiple Myeloma, Positioning Drug for Earlier-Line Use

on

FDA Delays Decision on Sanofi's Subcutaneous Sarclisa to July 23, 2026

on

Eli Lilly Acquires Kelonia Therapeutics for Up to $7 Billion to Bolster In Vivo CAR-T Pipeline

on

AstraZeneca's In Vivo CAR-T ESO-T01 Shows Promise in Multiple Myeloma with Remissions but One Death in China Trial

on

Bristol Myers Squibb Announces Positive Phase 3 Results for Mezigdomide in Multiple Myeloma

on

Johnson & Johnson Secures FDA Approval for Tecvayli and Darzalex Faspro Combo in Relapsed/Refractory Multiple Myeloma

on

Gilead Sciences Acquires Arcellx in $7.8 Billion Deal to Control CAR-T Cell Therapy

on

FDA Issues Draft Guidance on MRD and CR Endpoints for Accelerated Multiple Myeloma Drug Approvals

on

J&J Reports Positive Phase 3 MajesTEC-9 Results for Tecvayli in Earlier Multiple Myeloma

on

J&J's Tecvayli and Darzalex Combo Wins FDA's Proactive National Priority Voucher for Relapsed/Refractory Multiple Myeloma

on

AstraZeneca’s dual-targeting CAR-T AZD0120 shows similar response rates in Western and Chinese patients

on